Suppr超能文献

Clinical approach to drug resistance interpretation: expert advice.

作者信息

Clotet Bonaventura, Paredes Roger

机构信息

HIV Unit and Retrovirology Laboratory 'Irsicaixa' Foundation, Hospital Universitari Germans Trias i Pujol, UAB, Badalona, Catalonia, Spain.

出版信息

Curr Opin HIV AIDS. 2007 Mar;2(2):145-9. doi: 10.1097/COH.0b013e32801470f6.

Abstract

PURPOSE OF REVIEW

The body of knowledge regarding antiretroviral drug resistance is rapidly evolving as a result of extensive research and the continuous availability of new antiretroviral drugs. The interpretation of drug resistance tests may be difficult for clinicians not working in highly specialized healthcare environments. This may lead to inadequate treatment decisions, and can compromise the efficacy of antiretroviral regimens.

RECENT FINDINGS

Several studies have demonstrated better virological outcomes if the design of second and subsequent antiretroviral treatment lines incorporates expert advice in addition to genotypic resistance testing. The benefits of expert advice are limited to therapies to treat the second antiretroviral failure and probably extend to four or five failures. It confers no additional benefit if multiple and equally effective treatment options are available (i.e. after the first antiretroviral treatment failure) or if treatment alternatives are severely limited (i.e. after multiple treatment lines have failed). Conference calls provide a means of improving the availability of healthcare providers.

SUMMARY

Expert advice helps to optimize the design of salvage therapy after the second to the fourth or fifth treatment failure. It provides a continuous update to clinicians and can be made easily and broadly available through conference calls.

摘要

相似文献

1
Clinical approach to drug resistance interpretation: expert advice.
Curr Opin HIV AIDS. 2007 Mar;2(2):145-9. doi: 10.1097/COH.0b013e32801470f6.
3
Evaluation and management of early virological failure.
Curr Opin HIV AIDS. 2006 Sep;1(5):409-16. doi: 10.1097/01.COH.0000239853.99742.0f.
5
Issues in the design of trials comparing management strategies for heavily pretreated patients.
Curr Opin HIV AIDS. 2006 Nov;1(6):476-81. doi: 10.1097/01.COH.0000247388.00862.bb.
6
A regulatory perspective on the role of drug interactions in antiretroviral drug development.
Curr Opin HIV AIDS. 2008 May;3(3):325-9. doi: 10.1097/COH.0b013e3282f5f509.
8
Clinical trials for heavily pretreated patients: update in 2006.
Curr Opin HIV AIDS. 2006 Nov;1(6):495-501. doi: 10.1097/COH.0b013e328010f226.
9
New targets in antiretroviral therapy 2006.
Curr Opin HIV AIDS. 2006 Sep;1(5):437-41. doi: 10.1097/01.COH.0000239857.53108.ca.
10
Regulatory issues in developing new HIV protease inhibitors: risks and benefits.
Curr Opin HIV AIDS. 2008 Nov;3(6):676-80. doi: 10.1097/COH.0b013e3283136cb1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验